

Applicant : Mundy *et al.*
Serial No. : 09/805,840
Filed : March 13, 2001
Page : 2 of 6

Attorney's Docket No.: 10274-034001 / A061 US 002

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an anti-alpha4 integrin antibody or antigen binding fragment thereof.

2. (Previously presented) The method of claim 1, wherein the antibody or antigen binding fragment thereof is an anti-alpha4/beta1 (VLA-4) antibody or antigen binding fragment thereof.

3 (Canceled)

4. (Previously presented) The method of claim 1, wherein the anti-alpha4 integrin antibody or antigen binding fragment thereof is selected from the group consisting of a) an antibody or antigen binding fragment thereof that antagonizes the interaction of both VLA-4 and alpha4beta 7 with their respective alpha4 ligands; b) an antibody or antigen binding fragment thereof that antagonizes the interaction of VLA-4 with its alpha4 ligand; and c) an antibody or antigen binding fragment thereof that antagonizes the interaction of alpha4beta7 with its alpha4 ligand.

5. (Previously presented) The method of claim 4, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and an antigen-binding Fab, Fab', F(ab')₂ or F(v) fragment of a human, chimeric or humanized antibody.

Applicant : Mundy *et al.*
Serial No. : 09/805,840
Filed : March 13, 2001
Page : 3 of 6

Attorney's Docket No.: 10274-034001 / A061 US 002

6-8 (Canceled)

9. (Previously presented) The method of claim 1, wherein the composition is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg body weight of the antibody or antigen binding fragment thereof.

10-30 (Canceled)

31. (Previously presented) The method of claim 1, wherein the antibody or antigen binding fragment thereof is a human antibody or antigen binding fragment thereof or a humanized antibody or antigen binding fragment thereof.

32. (Previously presented) The method of claim 2, wherein the antibody or antigen binding fragment thereof is a human antibody or antigen binding fragment thereof or a humanized antibody or antigen binding fragment thereof.

33-39. (Canceled)

40. (Previously presented) The method of claim 2, wherein the anti-VLA-4 antibody or antigen binding fragment thereof is a humanized anti-VLA-4 antibody or antigen binding fragment thereof.

41. (Canceled)

42. (Previously presented) The method of claims 1 or 2, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody, or antigen-binding fragment thereof.

43. (Previously presented) The method of any one of claims 2, 32 or 40, wherein the anti-VLA-4 antibody or antigen-binding fragment thereof binds the alpha chain of VLA-4.

Applicant : Mundy *et al.*
Serial No. : 09/805,840
Filed : March 13, 2001
Page : 4 of 6

Attorney's Docket No.: 10274-034001 / A061 US 002

44. (Previously presented) The method of any one of claims 2, 32 or 40, wherein the anti-VLA-4 antibody or antigen-binding fragment thereof is a B epitope specific anti-VLA-4 antibody or antigen-binding fragment thereof.

45. (New) The method of any one of claims 1, 2, 4, 5, 9, 31, 32 or 40, wherein the method comprises administering a composition comprising an anti-alpha4 integrin antibody.

46. (New) The method of claim 42, wherein the method comprises administering a composition comprising an anti-alpha4 integrin antibody.

47. (New) The method of claim 43, wherein the method comprises administering a composition comprising an anti-alpha4 integrin antibody.

48. (New) The method of claim 44, wherein the method comprises administering a composition comprising an anti-alpha4 integrin antibody.